LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Amphastar Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

18.55 2.66

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.1

Max

18.89

Schlüsselkennzahlen

By Trading Economics

Einkommen

-18M

6.4M

Verkäufe

-12M

171M

KGV

Branchendurchschnitt

11.096

49.888

EPS

0.42

Gewinnspanne

3.751

Angestellte

1,976

EBITDA

-25M

14M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+21.41% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-201M

812M

Vorheriger Eröffnungskurs

15.89

Vorheriger Schlusskurs

18.55

Nachrichtenstimmung

By Acuity

40%

60%

124 / 344 Ranking in Healthcare

Amphastar Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Juni 2026, 21:51 UTC

Wichtige Markttreiber

Merlin Shares Rally After Defense Department's Design Review Wraps

4. Juni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. Juni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. Juni 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. Juni 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia to Enter Trading Halt

4. Juni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Juni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. Juni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. Juni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. Juni 2026, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. Juni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. Juni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. Juni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. Juni 2026, 18:47 UTC

Akquisitionen, Fusionen, Übernahmen

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. Juni 2026, 18:38 UTC

Ergebnisse

Money Quote: Tech Weakness in Context -- WSJ

4. Juni 2026, 18:24 UTC

Ergebnisse

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. Juni 2026, 16:58 UTC

Ergebnisse

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. Juni 2026, 16:38 UTC

Ergebnisse

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. Juni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. Juni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. Juni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer-Vergleich

Kursveränderung

Amphastar Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

21.41% Vorteil

12-Monats-Prognose

Durchschnitt 22 USD  21.41%

Hoch 25 USD

Tief 19 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amphastar Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

0

Buy

6

Halten

0

Sell

Stimmung

By Acuity

124 / 344 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat